Home / Male Impotence / Viagra / When Will Customers in the US Get Real Price Relief with Viagra?

When Will Customers in the US Get Real Price Relief with Viagra?

New generics to treat male impotence will soon usurp Viagra.

It’s coming. When Pfizer’s patent on Viagra expires in 2020, U.S. customers will able to save big on the male impotence drug.

That’s because other manufacturers are certain to rush to market with a less expensive generic alternative.

This could signal the start of a global price competition with the consumers as the real beneficiaries.

But did you know there’s a generic version of Viagra for male impotence already on the market?

Alternative to Viagra for Male Impotence?

Teva Pharmeceuticals USA Inc. reached a deal with Pfizer in 2016 to offer the first generic version of Viagra. Slidenafil citrate was released in early December one year later.

Buy Legal FDA-approved prescription medications like Viagra, Cialis, Levitra and Staxyn From Viamedic.com Buy Male Impotence Prescription Medications like Viagra, Cialis, Levitra and Staxyn From Viamedic.com

Teva is looking to capture some of the $1.14 billion CBS News said Pfizer captured through the sale of Viagra last year. With Pfizer’s patent that protects it from generic competitors expiring in the next couple of years, other companies, including Pfizer, are sure to offer alternatives. Pfizer has already countered with “the little white pill,” their own version of generic Viagra.

This is not the first time this has happened to Pfizer; once they lost the patent to Lipitor, the world’s best-selling drug for high cholesterol, lower-priced generics ended up costing them about $4 billion – and counting.

In fact, Eli Lilly’s patent on another male impotence drug, Cialis, expired in 2017.

The American Journal of Medicine reports that more than 18 million men suffer from male impotence. Therefore, the real beneficiary of all this medication wrangling is the American consumer.

Get your prescription medications online!

About Don Amerman

avatar
Don Amerman has spent more than three decades in the business of writing and editing. During the last 15 years, his focus has been on freelance writing. For almost all of his writing, He has done all of his own research, both online and off, including telephone and face-to-face interviews where possible. Don Amerman on Google+